please find enclosed unaudited financial results for the quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech reported Q1 FY26 standalone revenue from operations of Rs. 1,241.86 lakhs, up about 22.5% from Rs. 1,013.42 lakhs in Q1 FY25. Standalone profit after tax surged to Rs. 137.32 lakhs (EPS Rs. 0.76) from just Rs. 17.79 lakhs (EPS Rs. 0.12) a year earlier, helped by lower finance costs and a higher deferred tax credit. Consolidated PAT was Rs. 133.71 lakhs versus Rs. 16.64 lakhs in the year-ago quarter, with consolidated revenue at Rs. 1,251.16 lakhs. The board also approved allotment of 13,33,332 equity shares at Rs. 45 each (Rs. 35 premium) on conversion of warrants to two non-promoter entities, taking total share count to 2.13 crore shares. Auditor P. Murali & Co issued an unqualified review report with no qualifications or emphasis of matter.
Sharp YoY profit jump comes off a very low base, but the topline growth and margin expansion are meaningful positives for shareholders; however, dilution from the preferential warrant conversion and last quarter's allotment will weigh on EPS going forward.